The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Regeneron Pharmaceuticals

  • REGN
  • NASDAQ
  • Consumer Products
  • Latest 315.515
  • Currency US$
  • Change 1.025
  • Percent Change 0.326 %
  • Volume 559,465
  • Fri Jul 11, 2014 12:36 PM EDT NASDAQ data delayed 15 minutes.
  • Open 314.98
  • Previous Close 314.49
  • High 315.94
  • Low 310.75
  • Bidx1 315.24
  • Askx1 315.62
  • 52-week High03/06 352.49
  • 52-week Low08/19 227.64
  • Beta 0.839
  • Market Cap 31,819.69M
  • EPS 3.48
  • P/E 90.665
  • Forward P/E 26.93
  • PEG 1.27
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $2,290,820,000
  • Earnings $390,940,000
  • Return on Equity 18.78%

Cash Flow

  • Cash Flow --
  • Cash $461,850,000
  • Current Ratio 6.13

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $3,260,390,000
  • Liabilities $1,049,140,000
  • Liabilities-to-Equity Ratio 0.47

Price Ratios

  • Price to Sales 13.89
  • Price to Book 14.39
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings May 8 $0.98 Aug 5 $2.33
Surprises May 8 60.20% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 11, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Related Securities
Symbol Type Latest % Chg

Officers

  • P. Roy Vagelos, M.D. Chairman of the Board
  • Leonard S. Schleifer, M.D., Ph President; C.E.O. & Dir
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

777 OLD SAW MILL RIVER RD
TARRYTOWN, NY

Phone: (914)-347-7000
Fax: (516)-8699001

dbujnicki@kimcorealty.com
www.kimcorealty.com

Ideas & Discussion

Live Discussion of REGN on StockTwits